Omnicell (NASDAQ:OMCL) Issues FY 2025 Earnings Guidance

Omnicell (NASDAQ:OMCL - Get Free Report) issued an update on its FY 2025 earnings guidance on Thursday morning. The company provided earnings per share guidance of 1.650-1.850 for the period, compared to the consensus earnings per share estimate of 1.790. The company issued revenue guidance of $1.1 billion-$1.2 billion, compared to the consensus revenue estimate of $1.2 billion. Omnicell also updated its Q1 2025 guidance to 0.150-0.250 EPS.

Omnicell Stock Performance

NASDAQ OMCL traded up $0.73 on Friday, hitting $40.16. 797,215 shares of the company traded hands, compared to its average volume of 344,813. The business's 50 day moving average price is $44.21 and its 200-day moving average price is $43.38. Omnicell has a 52-week low of $25.12 and a 52-week high of $55.74. The company has a current ratio of 1.37, a quick ratio of 0.95 and a debt-to-equity ratio of 0.13. The company has a market capitalization of $1.86 billion, a price-to-earnings ratio of 148.75, a P/E/G ratio of 26.98 and a beta of 0.78.

Omnicell (NASDAQ:OMCL - Get Free Report) last posted its quarterly earnings data on Thursday, February 6th. The company reported $0.45 earnings per share for the quarter, missing analysts' consensus estimates of $0.57 by ($0.12). Omnicell had a net margin of 1.13% and a return on equity of 3.82%. Equities analysts expect that Omnicell will post 1.04 earnings per share for the current year.

Analyst Upgrades and Downgrades

OMCL has been the topic of several recent analyst reports. JPMorgan Chase & Co. raised their price objective on shares of Omnicell from $37.00 to $44.00 and gave the company a "neutral" rating in a research report on Thursday, November 21st. Barclays raised their price target on Omnicell from $39.00 to $58.00 and gave the company an "equal weight" rating in a report on Thursday, October 31st. StockNews.com lowered Omnicell from a "buy" rating to a "hold" rating in a research note on Tuesday, December 10th. Benchmark reiterated a "buy" rating and set a $62.00 target price on shares of Omnicell in a research report on Tuesday, February 4th. Finally, Bank of America lowered their price target on Omnicell from $54.00 to $46.00 and set a "neutral" rating on the stock in a report on Monday, January 6th. Five analysts have rated the stock with a hold rating and two have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, Omnicell currently has an average rating of "Hold" and an average price target of $52.33.

Insider Buying and Selling

In related news, Director Mark W. Parrish sold 12,000 shares of the business's stock in a transaction on Tuesday, December 10th. The shares were sold at an average price of $47.30, for a total value of $567,600.00. Following the sale, the director now owns 58,427 shares in the company, valued at approximately $2,763,597.10. The trade was a 17.04 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 2.64% of the stock is owned by company insiders.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.